From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
September 12, 2023
Philadelphia, PA, September 12, 2023 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that pharmaceutical pricing and regulatory expert and Vice President of Operational Consulting Jeff Baab will speak on the impact of the Inflation Reduction Act (IRA) at the Medicaid Drug Rebate Reporting Summit 2023, running September 18-20 in Chicago, IL.
The Challenges of Innovation: Operational and R&D Uncertainty from the IRATuesday, September 19, 11:10 amJeff Baab, Vice President of Operational Consulting, IntegriChainJudd Caulfield, Lead Counsel of the Oncology Business Unit, Takeda PharmaceuticalsHarmeet Dhillon, Head of Public Policy, GSK
During this session, these IRA subject matter experts will explore the ongoing and future ramifications of the Inflation Reduction Act. They will review where are in the process of operationalizing the IRA and what has happened since the most recent comment period. They will also share insights into the selection of drugs up for negotiation and why they were selected. With 80% of Pharma now reconsidering R&D of new products because of the IRA, these experts will discuss potential impacts and issues.
About IntegriChain’s Operational Consulting ServicesIntegriChain is a drug commercialization partner to a wide range of pharmaceutical manufacturers. From helping emerging companies plan and execute their first-time launch to supporting more than 65% of the top-50 largest manufacturers, IntegriChain’s solutions and services enable manufacturers to get their therapies to the right patients at the right time. IntegriChain’s Operational Consulting team offers broad operational and decision support practice areas that ensure commercialization and access strategies are put into action and deliver the expected results:
Roadmap to Launch: a proven blueprint for success in launching a new pharmaceutical product covering commercial analytics and support, compliance programs, and business and process guidance
Contracts & Pricing Consulting: from compliance and business planning to forecasting and analytics
Gross-to-Net (GTN) Consulting: includes GTN process assessment, GTN profitability assessment, and GTN modeling
ICyte Benchmarks: performance metrics based on the industry’s largest data set for thousands of therapy brands in the ICyte Platform including point-of-care segmentation and contract benchmarking
State Price Transparency Reporting: the industry’s largest provider of a full range of services for reporting, monitoring, and compliance
About IntegriChainIntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.
ContactJennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
